Day: June 21, 2021

LOWELL, Mass., June 21, 2021 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc., an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, is pleased to announce the addition of veteran Asia Pacific (APAC) commercial leader Sean Maynard to support its vision of becoming the trusted standard in the global microbial quality control (MQC) marketplace. In his role as APAC Commercial General Manager, Maynard reports to Scott White, VP of Global Sales, and is based in Singapore.

“I am incredibly excited to welcome Sean to our team,” said White. “I believe he has the right experience to lead our APAC expansion with both new and current customers who use our technology to support the manufacture of drug products such as biologics, sterile injectables, cell and gene therapies, and vaccines.”

Maynard’s background includes 15 years leading commercial sales teams in the APAC region, most recently achieving strong growth results as the APAC commercial leader for the microbiology division at Thermo Fisher Scientific, based in Singapore. He holds a program certificate from Harvard Business School, as well as a Diploma of Applied Science in Biological Chemistry Technology from University of Western Sydney.

Rapid Micro Biosystems CEO Robert Spignesi described Maynard’s hiring as a strategic move aimed at expanding the company’s presence in the APAC region. “There is significant demand for our Growth Direct^® platform from pharmaceutical manufacturers in Asia Pacific,” said Spignesi. “With Sean’s addition, coupled with continued investment in APAC, we believe we are well-equipped to capitalize on our significant growth potential in the region.”

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company’s flagship Growth Direct^® platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct^® platform brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, and global locations in Switzerland, Germany, and the Netherlands. For more information visit www.rapidmicrobio.com. Follow RMB at @rapidmicrobio or LinkedIn.

Contact(s)

Courtney Makolandra
Rapid Micro Biosystems
CMakolandra@rapidmicrobio.com
978.349.3200

Lens® decision intelligence platform connects the dots across a rapidly changing energy landscape

LONDON/HOUSTON/SINGAPORE, June 21, 2021 (GLOBE NEWSWIRE) — Wood Mackenzie, the leading provider of commercial intelligence for the world’s natural resources sector, today welcomes Quinbrook Infrastructure Partners as a development partner for the industry-leading Lens decision intelligence platform.

With its analytics-ready power and renewables data integrated into a single platform, Lens Power enables organisations to maximise investment opportunities in clean energy and be on the forefront of the energy transition.

Wood Mackenzie, a Verisk business (Nasdaq:VRSK), is collaborating with early adopters to design a power solution that provides a holistic understanding of what is happening in the world of energy, allowing organisations to analyse, screen and value assets or companies quickly and confidently to improve profitability and minimise risk.

Global Power Generation Assets by Energy Source

Source: Wood Mackenzie Lens Power

Matt Overbeck, Wood Mackenzie Senior Vice President, Head of Power and Renewables, said: “We’ve been in the power modelling business for a decade and have invested heavily to build out our energy transition division, both organically and through acquisition. We’re delighted to partner with Quinbrook, a specialist investment management firm focused exclusively on low carbon and renewable energy infrastructure investment and operational asset management.”

Quinbrook is widely recognised for making positive contributions towards Environmental, Social and Governance (ESG) investing, winning multiple awards for its Low Carbon Power Fund, and for its role as a value-add investment manager of clean energy infrastructure.

William Blake, Senior Vice President at Quinbrook, said: “Partnering with an established global energy data analytics company like Wood Mackenzie offers us a collaborative and responsive setting to discuss, implement, and improve the data, technology, and tools that aid our evaluation and monitoring of market trends and investment opportunities across the clean energy landscape.

“The energy transition to a zero-carbon future is driving a significant amount of investment opportunity, but it is also spawning new and complex risks for investment managers and market participants to navigate. Identifying, understanding, and actively addressing these risks head-on is fundamental to our approach in creating long-term and resilient asset value for our investors.

“Having access to the Wood Mackenzie Lens Power platform provides us with data-driven insight critical in supporting a disciplined underwriting when allocating our investor’s capital.”

Lens Power, integrating conventional power, solar, wind, energy storage, and hydrogen data sets in an integrated and easy-to-use platform, is attractive to energy players in the financial, utility, manufacturing, and oil and gas sectors.

About Wood Mackenzie Lens®
Wood Mackenzie’s Lens® platform is the industry standard in critical decision-support, harnessing the power of big data to provide answers to complex questions, enabling customers to manage their operations, processes, and capital swiftly and efficiently, wherever they are. https://www.woodmac.com/wood-mackenzie-lens-power/

For further information contact:
Laura Hindley
Senior Global PR Manager
laura.hindley@woodmac.com

About Wood Mackenzie
Wood Mackenzie, a Verisk Analytics business, is a trusted source of commercial intelligence for the world’s natural resources sector. We empower clients to make better strategic decisions, providing objective analysis and advice on assets, companies, and markets. For more information, visit: www.woodmac.com or follow us on Twitter @WoodMackenzie

WOOD MACKENZIE is a trademark of Wood Mackenzie Limited and is the subject of trademark registrations and/or applications in the European Community, the USA and other countries around the world.

About Quinbrook
Quinbrook Infrastructure Partners (www.quinbrook.com) is a specialist investment manager focused exclusively on lower carbon and renewable energy infrastructure investment and operational asset management in the U.S., U.K. and Australia. Quinbrook is led and managed by a senior team of power industry professionals who have collectively invested over US $8 billion of equity in energy infrastructure assets since the early 1990s, representing a total enterprise value of US $28.7 billion or 19.5 GW of power supply capacity. Quinbrook’s investment and asset management team has offices in Houston, London, Jersey, and the Gold Coast of Australia. Quinbrook’s global investment and portfolio company teams are actively developing and constructing a portfolio exceeding 17GW of onshore wind, solar PV, reserve peaking power, battery storage projects, grid support infrastructure, Virtual Power Plants and Community Energy Networks across the U.S., U.K., and Australia.

About Verisk
Verisk (Nasdaq:VRSK) provides predictive analytics and decision support solutions to customers in the insurance, energy and specialized markets, and financial services industries. More than 70 percent of the FORTUNE 100 relies on the company’s advanced technologies to manage risks, make better decisions and improve operating efficiency.

The company’s analytic solutions address insurance underwriting and claims, fraud, regulatory compliance, natural resources, catastrophes, economic forecasting, geopolitical risks, as well as environmental, social and governance (ESG) matters. Celebrating its 50^th anniversary, the company continues to make the world better, safer and stronger, and fosters an inclusive and diverse culture where all team members feel they belong. With more than 100 offices in nearly 35 countries, Verisk consistently earns certification by Great Place to Work.

For more: Verisk.com, LinkedIn, Twitter, Facebook and YouTube.

ZHUHAI, China, June 21, 2021 (GLOBE NEWSWIRE) — Jafron Biomedical, a pioneer in the blood purification industry, announced it’s founding the Global Advisory Board, which includes the world’s top medical experts in clinical research and critical care medicine.

The six members of the recently founded Global Advisory Board include: Prof. Claudio Ronco, Full Professor of Nephrology at the University of Padova, Italy; Prof. Rinaldo Bellomo, Head of Research of the Department of Intensive Care at the Austin Hospital of Melbourne, Australia; Prof. Thomas Rimmelé, Chief of the Department of Anesthesiology and Intensive Care Medicine of Edouard Herriot Hospital, Lyon, France; Dr. John R. Prowle, Senior Clinical Lecturer in Intensive Care Medicine at Barts, UK; Dr. Antoine Schneider, intensive care specialist at the Adult Intensive Care Unit at the Centre Hospitalier Universitaire Vaudois (CHUV) of Lausanne, Switzerland; Prof. Olivier Joannes-Boyau, Associate Head of Anesthesiology and Intensive Care department SUD at Bordeaux University Hospital, France.

This international non-commercial expert team funded by Jafron Biomedical aims to establish reliable, evidence-based data to further guide the application of hemoadsorption therapy. “Very pleased to join the advisory board. Through the screening of published clinical experience and further trials, the Advisory Board is committed to providing the medical community with further guidance and new solutions for the clinical usage of MOST (multi-organ support therapy),” said Prof. Rinaldo Bellomo.

“We are honored to have the support of an outstanding group of world-renowned clinicians and researchers in these fields. Their international leadership, extensive clinical expertise will be invaluable in the future development of Jafron”, stated Mr. Dong Fan, Founder and Chairman of Jafron. “This is a successful model of cross-field cooperation between research and industry in coordination with our Global Senior Consultant Mr. Jean Paul Menneguerre, which will make a great contribution in critical care and help more patients in the future.”

Prof. Claudio Ronco is a Full Professor of Nephrology at the University of Padova, Italy. He is also director of the Department of Nephrology and the International Renal ResearchInstitute (IRRIV) of San Bortolo Hospital, Vicenza, Italy. He is considered a pioneer in many areas of nephrology, including peritoneal dialysis, critical care nephrology, CRRT, cardiorenal syndromes, and wearable dialysis technology. He has received several international awards and invented the first CRRT machine for neonates CARPEDIEM (Cardio-Renal Pediatric Dialysis Emergency Machine).

Prof. Rinaldo Bellomo is Director of Intensive Care Research at the Austin Hospital; Professor of Intensive Care Medicine, University of Melbourne. Together with Dr. Prof. Ronco, Prof. Bellomo has been a lead investigator in the field of blood purification in sepsis, renal replacement therapy, and multi-organ support therapy for three decades with hundreds of publications in these fields of research and clinical practice.

Prof. Thomas Rimmelé is the Chairman of the Department of Anaesthesiology and Intensive Care Medicine at Edouard Herriot Hospital, Lyon, France, and Chairman of the Department of Organ Harvest Coordination for the Hospices Civils de Lyon. Prof. Rimmelé’s academic interests include blood purification for sepsis, acute kidney injury, renal replacement therapy in the intensive care unit, and simulation in healthcare. He is also the co-director of the simulation center at Lyon University.

Dr. John R. Prowle is an Honorary Consultant Physician in Intensive Care Medicine and Renal Medicine at The Royal London Hospital, Barts Health NHS Trust, London, UK. Dr. Prowle’s academic interests include the Pathogenesis, Diagnosis and Treatment, and Outcomes of Acute Kidney Injury, Continuous Renal Replacement Therapies in the ICU, Fluid Therapy, and Medical Complications of Major Surgery.

Dr. Antoine Schneider works as an attending physician at the Adult Intensive Care Unit, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. His area of research entitles renal perfusion, epidemiology of acute renal failure, and blood purification. He is currently the deputy chair of the AKI section of the ESICM and Course Director of the CRRT masterclass.

Prof. Olivier Joannes-Boyau, MD, is a full-time clinician in a 35 beds intensive care unit in a tertiary university hospital in Bordeaux (France). He has worked in the field of acute kidney injury, Renal Replacement Therapy, and multi-organ support therapy for about 20 years. He is the president of the ICU committee at the French society of anesthesiology and critical care (SFAR), a member of the European society of intensive care (ESICM), and the International Pan-Arab critical care medicine society (IPACCMS).

Please visit en.jafron.com to learn more about the hemoadsorption therapy and services offered.

About Jafron: Jafron Biomedical is an A-shared GEM listed corporation established in 1989. As pioneer enterprise in hemoadsorption industry, Jafron provides comprehensive solutions with full line hemoperfusion products including HA Series Hemoperfusion Cartridges, BS Bilirubin Adsorption Column and DNA Immunoadsorption Column. Annually there are over 3 million cases using Jafron hemoadsorption therapy in more than 80 countries, 6000 major hospitals worldwide. With the support of its new Global Advisory Board, Jafron strives to contribute the global medical community with more extensive research and guidance in blood purification and its cutting-edge technology.

Media Contacts
Company name: Jafron Biomedical Co., Ltd
Address: No. 98 Technology Six Road, High-tech Zone,Zhuhai City, China
Phone Number: +86-756-3689708
Website: en.jafron.com
Jafronclub: https://www.jafronclub.com

WATERLOO, Ontario, June 21, 2021 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq: DSGX) (TSX: DSG), the global leader in uniting logistics-intensive businesses in commerce, announces that online Swiss beauty vendor haar-shop.ch AG significantly improved order fulfillment productivity by over 40% and increased its warehouse utilization rate by more than one third by using Descartes’ cloud-based ecommerce warehouse management solution (WMS).

As haar-shop.ch‘s online business grew, it quickly became clear that manual fulfillment processes needed to be modernized. Its existing inventory management system did not offer advanced warehouse management capabilities such as “chaotic warehousing,” which speeds the put away process and maximizes warehouse space utilization. Employee processing and warehouse capacity quickly reached their limits. “We had sorted the shelves by brand, so every employee was required to memorize the product location in the warehouse,” said Markus Stoller, Head of IT at haar-shop.ch. “Our warehouse operations were inefficient as a result, and we couldn’t implement multi-order picking to improve employee productivity.”

With the Descartes solution, haar-shop.ch not only optimized the use of warehouse space, but also significantly increased shipping speed. “Our goals were exceeded. We gained over 35% storage space and increased productivity in order fulfillment by more than 40%,” Stoller explained. “By automating fulfillment processes, manual steps are reduced, which initiated massive changes in daily routines, but definitely paid off quickly. In fact, the benefits we had aimed for were achieved in only two weeks!”

Part of Descartes’ ecommerce solution suite, the Descartes Ecommerce WMS solution helps direct-to-consumer brands, ecommerce retailers, and traditional retailers rapidly scale in combination with providing a remarkable customer experience. The solution helps ensure that clients can ship on time, ship the right items, do not oversell existing inventory, and have full transparency into warehouse operations. The Descartes Ecommerce WMS solution is pre-integrated to major ecommerce platforms like Shopify, Magento or Shopware to accelerate implementation and time to value. Order information is automatically available to be executed via mobile driven multi-order pick-and-pack strategies and then fed into parcel shipment systems.

“The Descartes solution can help haar-shop.ch’s warehouse logistics processes scale along with their online store’s sales growth. We’re very proud to be able to support haar-shop.ch in offering its customers an outstanding shopping and delivery experience,” said Dirk Haschke, VP & General Manager, Ecommerce at Descartes. “For companies with ecommerce warehouse operations, excellence in order fulfillment is a key element for sustainable, successful business growth.”

About haar-shop.ch AG

Launched around 11 years ago, haar-shop.ch is the Swiss online specialist for professional hair and beauty products, now offering over 21,000 products. Based in Uetendorf in the canton of Bern, the company employs around 70 people. haar-shop.ch not only offers a wide range of products, but its customers also benefit from attractive prices and fast, reliable delivery. For more information, visit https://www.haar-shop.ch/en/.

About Descartes

Descartes (Nasdaq: DSGX) (TSX: DSG) is the global leader in providing on-demand, software-as-a-service solutions focused on improving the productivity, performance and security of logistics-intensive businesses. Customers use our modular, software-as-a-service solutions to route, schedule, track and measure delivery resources; plan, allocate and execute shipments; rate, audit and pay transportation invoices; access global trade data; file customs and security documents for imports and exports; and complete numerous other logistics processes by participating in the world’s largest, collaborative multimodal logistics community. Our headquarters are in Waterloo, Ontario, Canada and we have offices and partners around the world. Learn more at www.descartes.com, and connect with us on LinkedIn and Twitter.

Global Media Contact
Andra Schaz                                                       
Tel: +49 (0)89 961 60 61 66                            
aschaz@descartes.com

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ solution offering and potential benefits derived therefrom including potential efficiency gains and potential productivity improvements; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to differ materially from the anticipated results, performance or achievements or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the factors and assumptions discussed in the section entitled, “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities commissions across Canada including Descartes most recently filed management’s discussion and analysis. If any such risks actually occur, they could materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. We do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.